SCR7 Pyrazine, 5 MG

SCR7 pyrazine enhances the efficiency of precise genome editing with CRISPR/Cas9 up to 19-fold via inhibition of nonhomologous end joining (NHEJ). May be employed in an optimized CRISPR/Cas9 method to target methylation in a site-specific manner enabling maintenance of gene silencing in vitro and in vivo. SCR7 pyrazine exhibits greater activity against DNA ligases I and III than DNA ligase IV. Induces cancer cell death via inhibition of NHEJ and potentiates the effect of double strand break-inducing therapeutic modalities.